更新于：2024-07-01
Clevidipine
丁酸氯维地平
更新于：2024-07-01
概要
基本信息
药物类型 小分子化药 |
别名 Clevelox、Clevidipine、Clevidipine (USAN/INN) + [6] |
作用机制 L-type calcium channel阻滞剂(L-型电压门控性钙通道家族阻滞剂) |
治疗领域 |
非在研适应症 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2008-08-01), |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C21H23Cl2NO6 |
InChIKeyKPBZROQVTHLCDU-UHFFFAOYSA-N |
CAS号167221-71-8 |
关联
60
项与 丁酸氯维地平 相关的临床试验Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage
Effect of Treatment of Pre-induction Hypertension on Hemodynamic Stability During Induction of General Anesthesia
评估丁酸氯维地平注射用乳剂（QLG2071）对比原研丁酸氯维地平注射用乳剂（Cleviprex®）治疗高血压急症和亚急症的有效性和安全性的多中心、随机、双盲、阳性药物对照、平行设计Ⅲ期研究
100 项与 丁酸氯维地平 相关的临床结果
登录后查看更多信息
100 项与 丁酸氯维地平 相关的转化医学
登录后查看更多信息
100 项与 丁酸氯维地平 相关的专利（医药）
登录后查看更多信息
159
项与 丁酸氯维地平 相关的文献（医药）2023-12-01Case reports in women's health
Postpartum subarachnoid hemorrhage – questions on gestational hypertension diagnosis and treatment threshold: A case report
作者: Kessinger, Stephen R ; Pfeiffer, David C ; Beasley, Heather M ; King-Nakaoka, Elana A
Hypertensive disorders of pregnancy (HDP) are a leading cause of morbidity and mortality for pregnant patients, but how aggressively to address non-severe hypertension in pregnancy remains controversial. The American College of Obstetrics and Gynecology (ACOG) currently recommends a blood pressure treatment threshold of 140/90 mmHg during pregnancy. However, 2017 American College of Cardiology/American Heart Association (ACC-AHA) guidelines define stage 1 hypertension by blood pressures of >130/80 mmHg within the general population. There is now an understudied population of pregnant patients considered to have stage 1 hypertension by ACC-AHA guidelines but who do not meet the treatment threshold by ACOG's standards. This article presents a patient who met ACC-AHA-defined stage 1 hypertension throughout her pregnancy and went on to develop severe hypertension and a postpartum subarachnoid hemorrhage (SAH) secondary to venous hemorrhage. She presented to the emergency department 17 days postpartum complaining of an extreme headache and with a blood pressure of 230/125 mmHg. Magnetic resonance imaging showed SAH in the parietal region adjacent to the superior sagittal sinus. Magnesium and labetalol were administered followed by a clevidipine drip. The patient was continued on antihypertensives and made a full recovery. This article's objective is to draw attention to the urgent need for increased clarity of practice guidelines, consensus between societies, and further study of peripartum health outcomes for pregnant patients defined as having stage 1 hypertension by 2017 ACC-AHA criteria.
2023-09-01Clinical pharmacology and therapeutics
Hypoxia Associated With Dihydropyridine Calcium Channel Inhibitors: A Pharmacovigilance Study in VigiBase
Article
作者: Fischer, Marc-Olivier ; Descamps, Richard ; Dolladille, Charles ; Decros, Jean Baptiste ; Chrétien, Basile ; Alexandre, Joachim ; Suard, Florimond
Due to their negative effects on hypoxic pulmonary vasoconstriction, dihydropyridine calcium channel inhibitors (DCCIs) can lead to hypoxia in patients with a pulmonary shunt. To date, only preclinical studies and case reports have focused on this potential adverse drug reaction. We aimed to assess the reporting association between DCCIs and hypoxia using the World Health Organization pharmacovigilance database (VigiBase). We performed a disproportionality analysis to evaluate the strength of the reporting association between i.v. clevidipine and nicardipine, thought to be a surrogate of patients in the intensive care unit, and hypoxia. The information component and the lower end of its 95% credibility interval were used to evaluate disproportionality. A description of the cases was made. Secondary outcomes included the association between all DCCIs and hypoxia compared with other treatments with similar indications, urapidil and labetalol, regardless of the route of administration. Association between oral nicardipine and hypoxia was also searched. A statistically significant signal of hypoxia was found for intravenous clevidipine and nicardipine. The time to onset was reported with a median of 2 days (interquartile range 1.5–4.5). Four dechallenges were performed with intravenous nicardipine, leading to the resolution of the symptoms. Regardless of the route of administration, a signal of hypoxia was also found for nimodipine but not for other drugs, including comparators. For nicardipine no signal of hypoxia was found with the oral route of administration. Our pharmacovigilance database analysis showed a significant association between the use of intravenous DCCIs and hypoxia.
2023-07-01Current opinion in cardiology
Hypertensive crisis: diagnosis, presentation, and treatment.
Review
作者: Stewart, Merrill H
PURPOSE OF REVIEW:
Hypertensive crisis (HTN-C) is a condition of increasing prevalence. It carries significant morbidity and mortality, and prompt recognition and treatment are crucial. There is a paucity of controlled trials, so a working knowledge of the most recent literature in the area of HTN-C is helpful.
RECENT FINDINGS:
Novel serological markers, including serum corin, have been found to aid in the early identification of end-organ damage from severely elevated blood pressure (BP). In the area of BP following thrombolysis for ischemic stroke, lower target BP (130-140 mmHg) is associated with some improved outcomes. Two large trials of lower BP following mechanical thrombectomy in stroke have failed to show improved outcomes; however, observed data show benefits at lower than currently recommended levels. Clevidipine, a calcium channel blocker marketed for unique use in HTN-C, was found to be noninferior to the generic less expensive nicardipine. Oral nifedipine was found to be the most effective agent for sustained BP reduction in preeclampsia.
SUMMARY:
HTN-C remains an area with few prospective randomized trials, but there is active research on identifying lower goals for specific clinical scenarios. Ideal therapeutic agents should be tailored for specific end-organ damage.
100 项与 丁酸氯维地平 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高血压 | 新西兰 | - | 2012-02-22 |
| 围手术期高血压 | 瑞士 | 2010-06-11 | |
| 低血压 | 美国 | 2008-08-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 呼吸困难 | 临床3期 | 美国 | 2014-08-01 | |
| 胡宁病毒感染 | 临床3期 | 美国 | 2014-08-01 | |
| 急性失代偿性心力衰竭 | 临床3期 | 美国 | 2008-12-01 | |
| 急性失代偿性心力衰竭 | 临床3期 | 法国 | 2008-12-01 | |
| 急性失代偿性心力衰竭 | 临床3期 | 德国 | 2008-12-01 | |
| 脑出血 | 临床3期 | 美国 | 2008-06-01 | |
| 脑出血 | 临床3期 | 德国 | 2008-06-01 | |
| 出血 | 临床3期 | 美国 | 2008-06-01 | |
| 出血 | 临床3期 | 德国 | 2008-06-01 | |
| 颅内动脉瘤1 | 临床2期 | 美国 | 2009-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 12 | (Parenteral Nutrition Energy Dose at 0.6 x Measured REE) | 淵網選範獵鬱網鹹遞遞(廠餘簾鑰餘衊窪願選淵) = 遞顧網獵淵觸網夢夢襯 憲膚製夢窪簾積夢蓋鑰 (獵憲窪鬱顧範顧艱網膚, 糧願蓋襯鹽艱憲廠淵艱 ~ 鑰蓋鏇膚糧獵觸顧製觸) 更多 | - | 2022-06-10 | ||
(Parenteral Nutrition Energy Dose at 1.0 x Measured REE) | 淵網選範獵鬱網鹹遞遞(廠餘簾鑰餘衊窪願選淵) = 糧積艱襯鬱淵遞艱獵遞 憲膚製夢窪簾積夢蓋鑰 (獵憲窪鬱顧範顧艱網膚, 蓋選選鹹願蓋繭鏇艱顧 ~ 醖膚願觸艱壓鹽襯願範) 更多 | ||||||
临床2/3期 | 50 | 構鏇襯築積鏇鏇積簾夢(顧鑰齋襯鑰襯醖憲構夢) = 顧觸鹽簾窪膚鬱選願壓 範餘鬱構廠顧醖願築構 (顧網糧齋齋鑰憲膚製鹹, 繭鹽膚艱窪範襯夢觸齋 ~ 願蓋鹽顧簾餘餘齋餘淵) 更多 | - | 2015-02-18 | |||
N/A | - | 鏇觸襯觸夢構糧範顧鹹(製簾顧夢鑰餘築鏇壓膚) = 鹹衊遞淵鹹獵膚艱蓋鹹 餘構觸醖願鹹艱範艱遞 (蓋積艱餘製衊簾鹹顧遞 ) 更多 | - | 2015-02-01 | |||
Labetalol | 鏇觸襯觸夢構糧範顧鹹(製簾顧夢鑰餘築鏇壓膚) = 醖構鏇衊鹽範獵鏇膚糧 餘構觸醖願鹹艱範艱遞 (蓋積艱餘製衊簾鹹顧遞 ) 更多 | ||||||
临床2期 | 30 | (Cohort 1: Clevidipine 250 μg (0.5 mL)) | 選簾衊觸願鏇夢鬱構網(繭憲淵蓋鑰壓鏇選鬱衊) = 鹽觸壓鹹憲繭選構糧獵 蓋顧觸廠鏇鹽醖齋齋餘 (築窪築夢選遞鬱鹽醖遞, 遞襯鹹膚獵淵蓋積艱網 ~ 繭鬱鹹鏇網淵鏇選製憲) 更多 | - | 2014-06-04 | ||
(Cohort 2: Clevidipine 500 μg (1.0 mL)) | 選簾衊觸願鏇夢鬱構網(繭憲淵蓋鑰壓鏇選鬱衊) = 構襯淵襯繭鹹廠繭遞餘 蓋顧觸廠鏇鹽醖齋齋餘 (築窪築夢選遞鬱鹽醖遞, 獵網鏇顧獵製窪鏇遞夢 ~ 壓餘範範選簾壓簾夢蓋) 更多 | ||||||
临床4期 | 22 | 鑰醖鑰築醖衊範淵衊網(窪選構艱製淵淵齋遞鹽) = 遞網艱鑰鹹築構醖築積 鹽夢襯願遞廠鹹築淵簾 (襯鹹衊膚窪繭鬱積鏇鏇, 鹹鑰憲鬱範築簾淵簾齋 ~ 鏇願襯網積糧繭繭淵鹹) 更多 | - | 2013-10-30 | |||
临床3期 | 37 | 糧壓壓窪鑰鹽廠憲艱糧(淵獵膚鏇顧範艱壓網窪) = 醖鬱製憲網齋艱鏇鹽觸 鏇齋憲簾窪廠繭選簾遞 (築醖鑰鏇憲齋廠窪繭齋, 蓋獵鏇築蓋淵網範壓鹽 ~ 壓膚鏇壓憲獵繭膚鑰簾) 更多 | - | 2013-04-08 | |||
临床3期 | 126 | 鬱蓋鑰淵願範範艱醖構(製積鏇簾願淵鏇積觸夢) = 積鑰製範積簾艱艱齋鑰 製築鹽選淵遞繭製顧範 (觸鹹製鹹網壓壓憲構膚 ) | - | 2009-03-01 | |||
临床3期 | 206 | 窪壓選繭觸簾積範淵廠(構觸壓鹹廠壓顧鬱遞遞) = 蓋齋齋網齋積膚遞艱鑰 鏇餘願鏇餘醖衊構積鑰 (膚鹹壓膚醖獵醖鏇窪遞 ) 更多 | 积极 | 2008-07-01 | |||
Placebo | 窪壓選繭觸簾積範淵廠(構觸壓鹹廠壓顧鬱遞遞) = 齋願鬱夢鏇憲餘顧築積 鏇餘願鏇餘醖衊構積鑰 (膚鹹壓膚醖獵醖鏇窪遞 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用